There are 2185 resources available
806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Presenter: Armin Ghobadi
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
807MO - High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients
Presenter: Lei Yu
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
808MO - Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T cell therapy
Presenter: Patrick Veit-haibach
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
LBA18 - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+; advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINY-Breast12 primary results
Presenter: Nancy Lin
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
LBA38 - Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308)
Presenter: Dewei Li
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
603O - First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
Presenter: Robin Guo
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
1925MO - Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)
Presenter: Sophie Cousin
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
988O - A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma
Presenter: Gustav Ullenhag
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
LBA80 - Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST “Ribociclib/HDM201” basket study
Presenter: Mehdi Brahmi
Session: Mini oral session: Sarcoma
Resources:
Abstract
340O - Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)
Presenter: Barbara Pistilli
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract